论文部分内容阅读
目的:观察附子理中丸对脾阳虚证大鼠骨骼肌肌球蛋白ATP酶(M-ATP酶)活性的影响。方法:18窝新生大鼠,同窝9只匹配、体质量均衡随机分入9组;前5组不切除甲状腺为获得性脾阳虚;后4组切除甲状腺为发育性脾阳虚。第1d切除部分甲状腺,第42d切除肩胛骨间棕色脂肪,第56d开始高脂饲养,第70d开始用药防治,第98d取左侧腓肠肌,冰冻切片,M-ATP酶染色,形态计量单位体积相对总活性,t检验比较组间差别。结果:获得性脾阳虚中,模型组M-ATP酶活性比对照组升高26.10%(P<0.01),高脂组比模型组降低10.40%(P<0.01),凉治组比高脂组降低21.39%(P<0.01),温治组比高脂组升高34.89%(P<0.01)。发育性脾阳虚中,模型组M-ATP酶活性比对照组升高101.56%(P<0.01),高脂组比模型组降低19.98%(P<0.01),凉治组比高脂组升高8.01%(P<0.01),温治组比高脂组降低18.65%(P<0.01)。与获得性脾阳虚比较,性脾阳虚模型组、高脂组、凉治组和温治组分别升高59.85%(P<0.01)、42.76%(P<0.01)、96.14%(P<0.01)和18.29%(P<0.01)。结论:附子理中丸回调脾阳虚大鼠骨骼肌M-ATP酶活性,对发育性脾阳虚大鼠的作用效能大于获得性脾阳虚的作用效能。
Objective: To observe the effect of Fuzi Lizhong Wan on skeletal muscle myosin ATPase (M-ATPase) activity in rats with spleen Yang deficiency syndrome. METHODS: Eighteen newborn rats and 9 identical litters were divided into 9 groups randomly. The first five groups were given thyroidectomy for spleen yang deficiency. The latter four groups were for developmental spleen yang deficiency. On the first day, some of the thyroid glands were excised. On the 42nd day, the brown fat was removed from the scapula. The high fat diet was started on the 56th day. The medication was started on the 70th day. The left gastrocnemius, frozen section, M-ATPase staining, t test to compare the differences between groups. Results: Compared with the control group, the M-ATPase activity of model group was increased by 26.10% (P <0.01) and that of the model group was 10.40% (P <0.01) Group decreased by 21.39% (P <0.01), and the temperature-treated group increased by 34.89% (P <0.01) compared with the hyperlipidemia group. Compared with control group, M-ATPase activity in model group was increased by 101.56% (P <0.01), that in model group was decreased by 19.98% (P <0.01) High 8.01% (P <0.01), Wenzhi group reduced 18.65% (P <0.01) than the high fat group. Compared with acquired deficiency of spleen - yang syndrome, the model group with spleen yang deficiency, hyperlipidemia group, Liangzhi group and Wenzhi group increased 59.85% (P <0.01), 42.76% (P <0.01), 96.14% 0.01) and 18.29% (P <0.01). Conclusion: Fuzi Li Zhong Pill can revise the M-ATPase activity of skeletal muscle in rats with spleen-yang deficiency and its effect on developing spleen-yang deficiency rats is greater than that of acquired spleen-yang deficiency syndrome.